News
10-20-2013, 11:10 PM
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.
More... (http://www.news-medical.net/news/20131021/New-small-molecule-inhibitor-shows-promising-results-in-drug-resistant-melanoma-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20131021/New-small-molecule-inhibitor-shows-promising-results-in-drug-resistant-melanoma-breast-cancer.aspx)